Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05011513 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1,440
- Enrollment target
NCT05011513 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 1,440 participants.
The verdict
NCT05011513, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1,440 participants
- Enrollment target
Study Summary
The primary hypothesis to be tested is whether or not there is a difference in time to sustained alleviation of all targeted COVID-19 signs and symptoms through Day 28 between PF-07321332/ritonavir and placebo.
Interventions
- DRUG Placebo
- DRUG Ritonavir
- DRUG PF-07321332
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,440 participants |
| Start Date | 2021-08-25 |
| Est. Completion | 2022-07-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05011513
The ClinicalTrials.gov registry entry for NCT05011513 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1,440 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05011513 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05011513 about?
NCT05011513 is a clinical study titled "Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).". The primary hypothesis to be tested is whether or not there is a difference in time to sustained alleviation of all targeted COVID-19 signs and symptoms through Day 28 between PF-07321332/ritonavir and placebo.
What is the current status of trial NCT05011513?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1,440 participants. The study started on 2021-08-25. Estimated completion is 2022-07-25.
What interventions are being tested in trial NCT05011513?
The interventions under investigation include: Placebo (DRUG), Ritonavir (DRUG), PF-07321332 (DRUG).
Who is sponsoring clinical trial NCT05011513?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.